GlycoNex Incorporation (TPEX:4168)
21.70
+0.10 (0.46%)
Oct 20, 2026, 1:30 PM CST
GlycoNex Incorporation Revenue
GlycoNex Incorporation had revenue of 1.90M TWD in the quarter ending June 30, 2026, a decrease of -88.15%. This brings the company's total for the last twelve months to 22.21M, down -36.49% year-over-year. In the year 2025, GlycoNex Incorporation had annual revenue of 37.86M with 157.54% growth. That makes GlycoNex Incorporation the 44,152nd largest company in the world by revenue and 2,175th in Taiwan.
Revenue (ttm)
22.21M
Revenue Growth
-36.49%
P/S Ratio
109.93
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.44B
Revenue by Geography
- Japan 37.82M 99.9%
- Taiwan 42.00K 0.1%
Fiscal year ended Dec 31, 2025 See the full GlycoNex Incorporation breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.86M | 23.16M | 157.54% |
| Dec 31, 2024 | 14.70M | 12.16M | 478.32% |
| Dec 31, 2023 | 2.54M | -27.54M | -91.55% |
| Dec 31, 2022 | 30.09M | 24.61M | 449.50% |
| Dec 31, 2021 | 5.48M | 5.02M | 1,113.97% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.05B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 467.69M |
| HeXun Biosciences | 308.21M |
| G&E Herbal Biotechnology | 215.61M |
| 3D Global Biotech | 159.19M |
| Gwo Xi Stem Cell Applied Technology Co. , | 157.86M |
| Intech Biopharm | 48.55M |